However, it’s noteworthy that heightened endogenous FGF21 levels have been documented in people with obesity, NAFLD, and diabetes [33–35], indicative of a state of FGF21 resistance [36]. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.